GANX · Gain Therapeutics, Inc. · Share Buybacks
$1.26
-0.03 (-2.33%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our projected cash outflows for the upcoming periods raise substantial doubt about our ability to continue as a going concern for at least 12 months from the issuance of the financial statements included elsewhere in this Quarterly Report. We will need to raise additional capital to fund continued operations beyond the second quarter of 2027.”View the 10-Q filed Aug 11, 2026
Market Cap
$54.99M
Shares
43.64M
Volume · Oct 23
645.03K
Avg daily vol (3M)
503.57K
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| 2024-09-06 | — | $50,000,000 | $28,000,000 as of 2025-12-31 | — | 10-Q , filed 2026-08-11 |